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a b s t r a c t
The presented project started by screening a library consisting of natural and natural based compounds
for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activity. Active com-
pounds were chemically clustered into groups and further tested on the human cholinesterases isoforms.
The aim of the presented study was to identify compounds that could be used as leads to target two key
mechanisms associated with the AD’s pathogenesis simultaneously: cholinergic depletion and beta amy-
loid (Ab) aggregation. Berberin, palmatine and chelerythrine, chemically clustered in the so-called iso-
quinoline group, showed promising cholinesterase inhibitory activity and were therefore further
investigated. Moreover, the compounds demonstrated moderate to good inhibition of Ab aggregation
as well as the ability to disaggregate already preformed Ab aggregates in an experimental set-up using
HFIP as promotor of Ab aggregates. Analysis of the kinetic mechanism of the AChE inhibition revealed
chelerythrine as a mixed inhibitor. Using molecular docking studies, it was further proven that cheleryth-
rine binds on both the catalytic site and the peripheral anionic site (PAS) of the AChE. In view of this, we
went on to investigate its effect on inhibiting Ab aggregation stimulated by AChE. Chelerythrine showed
inhibition of fibril formation in the same range as propidium iodide. This approach enabled for the first
time to identify a cholinesterase inhibitor of natural origin—chelerythrine—acting on AChE and BChE with
a dual ability to inhibit Ab aggregation as well as to disaggregate preformed Ab aggregates. This com-
pound could be an excellent starting point paving the way to develop more successful anti-AD drugs.
! 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Alzheimer’s disease (AD) is a seriously damaging neurodegener-
ative disease affecting human health. The most important changes
observed in the brain of AD patients are the appearance of amyloid
beta (Ab) plaques, neurofibrillary tangles and a dramatic decrease
in hippocampal and cortical levels of the neurotransmitter acetyl-
choline (ACh). A wealth of evidence indicates that the pathological
accumulation of Ab in the brain relates to a variety of damaging
events that ultimately causes neuronal destruction and cholinergic
deficit.1
Impairment of ACh-mediated neurotransmission involving ACh
depletion is a key component of AD, thus the rationale behind the
use of cholinesterase inhibitors (ChEI) in this pathology has primar-
ily consisted in providing an amplification of the deprived choliner-
gic activity. The ChEI donepezil, galanthamine and rivastigmine
represent the first line pharmacotherapy for mild to moderate AD.
Interest in ChEI has also increaseddue tofindings supporting cholin-
esterase’s involvement in b-amyloid peptide fibril formation during
AD pathogenesis.2 Various studies have indeed supported that ChEI
can prevent Ab oligomerization, thus displaying both antiamyloid
and neuroprotective disease-modifying effects.3
The peripheric anionic site (PAS) of AChE was identified as the
locus where the interaction between the enzyme and Ab apparently
takes place.4 By contrast, no significantly enhanced Ab1–40 fibril for-
mation was observed when co-incubating the peptide with BChE.2
In fact, after several years of research with cholinesterases, the con-
nection of BChE with amyloidogenesis still remains unclear.5,6
However, it has been established that in the status of advanced
AD, BChE hydrolyses the already depleted acetylcholine levels thus
exacerbating the cholinergic imbalance.7 Moreover, Holmes et al.
proposed that low-activity BChE in AD patients correlates with
better cognitive function.8 In view of that, our study did not only
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concentrate on AChE inhibition, but also included BChE. We there-
fore focused on the identification of dual inhibitors of AChE and
BChE, which could increase the likelihood of finding promising
leads/drug candidates against AD. Based on the complex multifac-
torial nature of AD, developing compounds able to act on multiple
targets within the biological network simultaneously and thus re-
trieve the biological equilibrium has been claimed as a successful
approach.9 This strategy can be achieved in several ways. The com-
bined administration of AChE inhibitors together with NMDA
receptor antagonists is one example of this approach. However, it
has the major drawback that every compound has to be tested by
its own as well as in combination in terms of safety and efficiency.
Another way is to identify/develop a single drug able to act as mul-
ti-target-directed ligand. Some examples are the synthetic AChE
inhibitors ladostigil (TV-3326) and memoquin. Ladostigil, currently
being evaluated in clinical studies, also inhibits themonoamine oxi-
dase, modulates the amyloid precursor protein processing and has
antioxidant properties.10 In turn, memoquin exhibits antioxidant
functions, acts as b-secretase inhibitor, Ab anti-aggregant and
influences tau hyperphosphorylation.11 In particular, molecules
with ability to destabilize preformed Ab aggregates together with
inhibitory properties of Ab aggregation and cholinesterases activity
could be regarded as especially desirable.
So far, two of the three ChEIs licensed for the treatment of
dementia in western countries are of natural origin (galanthamine
and rivastagmine, a semi-synthetic derivative of physostigmine)
and another natural compound, huperzine A, isolated from Huper-
zia serrata (Thunb.), is a licensed cholinesterase inhibitor used as
anti-AD drug in China.12 Therefore, it seems likely to find new
anti-AD pharmacophores when exploring natural sources. More-
over, natural-based compounds are often better tolerated than
their synthetic congeners which is a favorable aspect on the pro-
cess of approval of new drugs.13 Thus, in this contribution we
screened a commercial library of natural and natural-based com-
pounds (Supplementary Table S1) for their AChE and BChE inhibi-
tory activity. Of the whole library (502 compounds) 23 compounds
were identified as either active on AChE, BChE or both (dual inhib-
itors), and they were clustered into six different groups according
to their chemical structures and not according to their biosynthetic
routes, which is the general way of classifying natural compounds.
Follow-up studies of the compounds were conducted and the iden-
tification of structural key requirements necessary for the biologi-
cal activity was attempted.
2. Results and discussion
2.1. Bioactivity screening
The screening of the natural compound library for inhibition of
AChE’s and BChE’s hydrolase activity was done using a kinetic as-
say based on Ellman’s reaction.14 To ensure high quality from the
screening viewpoint, the following statistical parameters were
used to evaluate the assay: signal-to-noise (S/N) ratio, signal-to-
background (S/B) ratio, signal window coefficient (Z0 factor) and
coefficient of variation of the assay (CVA). An assay with Z0 P 0.5
is regarded as a good-to-excellent assay, depending on the proxim-
ity to Z0 = 1 (the ideal assay).15 In the screening presented herein
the acceptance parameters were set as: Z0 > 0.5, S/N > 15 and S/
B > 15. Three times the standard deviation of the maximal signal
(negative controls, samples containing the uninhibited enzyme)
was used to determine the theoretical hit limit, which resulted in
40% of inhibition. However, since the screening was planned at
an average compound concentration in the micromolar range
(17.5 lM), the threshold was empirically set higher, at 50% inhibi-
tion, to identify more potent inhibitors.
In total, 23 compounds displayed inhibitory activity towards
AChE (electric eel origin) and/or BChE (horse origin). The primary
screening results of all the tested compounds can be found in the
Supplementary Table S1. Both non-human enzymes are frequently
used in primary screening campaigns because they represent a
cost-effective way to generate a first sound bioactivity profile of
compound libraries.16 Compounds were regarded as active if they
scored over 50% inhibition of the hydrolase activity. This activity
limit guaranteed to identify compounds with IC50 values below
33 lM, the highest compound concentration in the primary
screening assay.
Figure 1 represents the results of the initial screening against
AChE and BChE. Three compounds were able to inhibit more than
50% of the activity of both cholinesterases and are located in quad-
rant I (represented by triangles). Quadrant II includes six com-
pounds (circles) showing an AChE inhibition over 50% but with a
BChE inhibition lower than 50% thus giving initial evidence that
these compounds can be regarded as selective AChE inhibitors. Con-
versely, the 14 compounds located in the quadrant IV (squares),
were found as selective BChE inhibitors. The majority of the com-
pounds in the library, located in quadrant III (diamonds), did not ex-
hibit more than 50% inhibition neither on AChE nor on BChE.
2.2. Exploration of the chemical space occupied by the library
After screening the collection on AChE and BChE inhibition, the
substances were mapped using ChemGPS-NP. Based on a principle
component analysis (PCA) with eight dimensions describing 2D
physico-chemical parameters (e.g., size, shape, aromaticity, lipo-
philicity and flexibility) for a reference set, ChemGPS-NP allows
to map new compounds into the chemical space.17 Supplementary
Figure S1 shows that the compounds are widely distributed over
the chemical space. However, the 23 active hits inhibiting ChEs
(selective for AChE or BChE as well as unselective inhibitors)
clearly locate within the same area (colored spheres). Thus, it can
be concluded, that compounds with limited flexibility (PC4) and
low molecular weight (PC1), a certain degree of aromaticity (posi-
tive PC2) as well as lipophilicity (positive PC3) possess a higher
likelihood to display ChE inhibition. This information can be com-
pared with data we have obtained from a synthetic library consist-
ing of compounds based on naturally existing scaffolds that was
screened toward selective BChE inhibition.18,19 Active representa-
tives of this library were located in the same region of the chemical
space as the compounds identified as ChE inhibitors in the pres-
ent study. Only the flexibility (as determined by PC4) differed:
Figure 1. Correlation plot of the electric eel AChE and horse BChE inhibitory
activities of the entire natural compound library (502 compounds). Unselective ChE
inhibitors are located in quadrant I (triangles), quadrant II shows selective AChE
inhibitors (circles), quadrant III contains all inactive compounds (diamonds) while
the selective BChE inhibitors are found in quadrant IV (squares; only 12 data points
are visible in the graph instead of 14 due to an overlap among the compounds).
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synthetic diarylimidazoles seemed to require a higher degree of
flexibility to act as BChE inhibitors when compared to natural
products. However, molecular flexibility is a property that seems
to differ between natural and synthetic molecules, with natural
compounds typically displaying less flexibility than their synthetic
counterparts.20 This is also reflected in the compound library used
herein as only approximately a quarter of the natural compounds
were located on the positive side of the PC4 axis. Elucidation of
the chemical space occupied by the active hits thus revealed valu-
able information about the physico-chemical parameters that are
essential for ChE inhibition.
2.3. Chemical clustering of the active compound groups
To continue with an in-depth characterization of the active mol-
ecules, an exclusion criterion was applied to the general group of
23 hits. The criterion was based on: (i) if they were known ChE
inhibitors and (ii) if they have poor chemical stabilities. Following
the first element, the known ChE inhibitors galanthamine, ebelac-
tone B, huperzine A and physostigmine were excluded from further
investigation. However, their identification demonstrated once
more the accuracy of the kinetic assay used. Following the second
element, the original hits solasodine, tetrahydroalstonine and har-
mine were also excluded, as they were shown to be chemically
unstable in the assay buffer during the reconfirmation process
(data not shown). Thus, a total of 16 hits out of the original 23 were
taken up for further investigation (Tables 1 and 2). The results pre-
sented earlier (Fig. 2) suggested that the active hits shared a spe-
cific chemical space, most likely given by common chemical
scaffolds. Indeed, upon close examination of these molecules, the
remaining 16 compounds were found to share common scaffolds
and based on those similarities they were structurally clustered
into six groups (Tables 1 and 2). This structural sorting provided
a better view towards the most promising and interesting func-
tional moieties within the natural compounds studied.
2.3.1. Quinazolines
The first group (Table 1) comprises compounds with the qui-
nazoline scaffold and includes peganole, vasicine and desoxypega-
nine. The first two (peganole and vasicine) were shown to be
selective BChE inhibitors and hence were further studied concern-
ing their activity towards the human BChE (hBChE). Peganole was
less active compared to the horse BChE with an IC50 value higher
than 20 lM but vasicine showed good inhibitory activity also
against the hBChE (3.13 ± 0.79 lM). Desoxypeganine displayed
similar activity on both BChE and AChE indicating that it was a
non-selective inhibitor. From a chemical point of view it is highly
interesting that these three representatives differ in the position
and/or presence of only one hydroxy group. In peganole and vasi-
cine, the position of the OH group determines the potential of the
BChE inhibition and indicates that OH-substitution in position 9
(as in the vasicine) favors the selective enzyme inhibition whereas
an OH group in position 4 of the quinazoline scaffold (present in
peganole) results in a decrease of activity. The loss of the hydroxy
group as is the case in desoxypeganine results in an unselective
inhibition of both enzymes.
The quinazoline scaffold has been used as a model for the syn-
thesis of hybrid compounds out of quinazolinimines and lipoic acid
with the most active compound showing an IC50 value on BChE of
5.7 nM (82-fold higher than the potency toward AChE).21 In an-
other study, the covalent connection of two quinazolinimine
molecules by different hydrocarbon spacers resulted in one highly
potent and selective BChE inhibitor (IC50 of 3 nM).16 Moreover, a
quinazoline derivative, coded as SMER28, has been described as
an enhancer of autophagy, a cellular pathway responsible for
the degradation of aggregated proteins, that is, beta amyloid
aggregates.22 Thus, because this quinazoline chemical class has al-
ready attracted the attention of medicinal chemists, we did not fur-
ther investigate it.
2.3.2. Indoles
The second group (Table 1) consists of four indole representa-
tives which were found to be selectively active on BChE, with
IC50 values ranging from 4.97 to 10.63 lM. Interestingly, three
out of the four compounds (nitrarine, hirsutine and catharanthine)
showed slightly higher activity towards the human BChE when
compared to the horse enzyme. As can be seen from these data,
the side chain fused to the indole motif does not critically influ-
ence the potential of the BChE inhibition. Indole derivatives have
not been intensively investigated in terms of their ability to inhibit
cholinesterases in the context of AD. Recently, Pereira et al. studied
the inhibitory effect of Catharanthus roseus root alkaloids on AChE
and described catharanthine as not active.23 This is in accordance
with our results as we identified this indole derivative as a selec-
tive BChE inhibitor, not active upon AChE. To the best of our
knowledge, no biological data have been described so far for
nitrarine. Rauwolscine, also known as isoyohimbine or alpha-
yohimbine, is a known highly potent a2-adrenergic receptor
antagonist.24 In 1999, Shimada et al. reported a protective effect
of hirsutine on glutamate-induced neuronal death.25 Moreover, it
also showed a vasodilating activity in the same micromolar
range26 as the herein described selective BChE activity. Due to
the fact that representatives of this group exhibited only modest
BChE inhibitory activity we decided not to continue with more fol-
low-up studies.
2.3.3. Steroid alkaloids
Within the group of active steroid alkaloids (Table 1), sevedin-
dione and veratramine caused a selective inhibitory activity to-
wards BChE. For sevedindione, no biological activities have been
described so far. This compound showed an IC50 value on horse
BChE of 3.68 ± 0.26 lM and displayed an approximately ten times
higher potency on human BChE with an IC50 of 0.27 ± 0.04 lM.
Veratramine showed a weaker activity than sevedindione towards
horse BChE (IC50 of 10.78 ± 1.13) and human BChE (IC50 of
19.46 ± 0.95 lM). Wang et al. proved a hypotensive effect of
veratramine in in vivo experiments and also demonstrated a de-
crease in heart rate under the influence of this compound.27 More-
over, they did not observe any side effects during their studies.
Compared to veratramine, sevedindione possesses a continuous
steroidal ring system together with a tertiary nitrogen. Sevedindi-
one has good inhibitory potential of the human enzyme, but lower
if compared to various compounds (i.e., phenothiazines, cymserine
analogues and isosorbide-based compounds) that have been re-
cently reported as selective BChE inhibitors.28–30 Therefore, this
group was also excluded from further investigations.
2.3.4. Polycyclic ring systems
E6 berbamine and oxyacanthine sulfate are clustered together
within the group of polycyclic ring systems. Both compounds dis-
played similar activity on horse BChE with 4.20 ± 0.21 lM for E6
berbamine and 4.10 ± 0.20 lM for oxyacanthine sulfate. Moreover,
both compounds showed a two-fold improved activity on the
human enzyme (E6 berbamine 2.14 ± 0.07 lM and oxyacanthine
sulfate 1.89 ± 0.07 lM). These compounds mainly vary in the sub-
stitution pattern of the (substituted) hydroxy group as well as the
position of the ether bridge connecting the two phenyl rings. E6
berbamine bears a para-nitro-benzoyl substituent on the OH
group, as opposed to the oxyacanthine sulfate which has a free
hydroxyl group. As no differences in activity were detected
between these two molecules, it seems that the electronic and
steric effects of the para-nitro-benzoyl substituent are not relevant.
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Table 1
Clustered chemical groups from the compounds present in the natural products collection and their natural sources
Group Compound Examples of plant sources Structure IC50 (lM)
BChE hBChE AChE




11.39 ± 0.37 >20 n.a.




2.53 ± 0.36 3.13 ± 0.79 n.a.




11.94 ± 0.05 n.t. 11.81 ± 0.06






10.63 ± 0.37 9.01 ± 0.22 n.a.






H 4.97 ± 0.33 1.97 ± 0.04 n.a.










8.38 ± 0.54 13.68 ± 1.48 n.a.







5.17 ± 0.18 3.17 ± 0.11 n.a.




























HO 10.78 ± 1.13 19.46 ± 0.95 n.a.











4.20 ± 0.21 2.14 ± 0.07 n.a.















4.10 ± 0.20 1.89 ± 0.07 n.a.








H2O 7.37 ± 0.03 1.23 ± 0.07 n.a.











n.a. n.a. 22.72 ± 0.64











Overview of the biological activity (IC50 values in lM) of the isoquinoline group together with their natural sources
Group Compound Structure Examples of plant sources IC50 (lM)


























Chelidonium majus L., Sanguinaria canadensis L., Dicranostigma lactucoides
Hook. f. et. Thoms., Macleaya, Bocconia, Zanthoxylum spp.59
3.78 ± 0.15 1.54 ± 0.07 6.33 ± 0.93 10.34 ± 0.24 4.20 ± 0.43 13.03 ± 2.89
AChE = electric eel AChE; hAChE = human AChE; BChE = horse BChE; hBChE = human BChE; Ab1–40 aggreg. = inhibition of Ab1–40 aggregation; Ab1–40 disaggreg. = disaggregation of preformed Ab1–40 aggregates; n.a. = not active;










So far, there are no reports present describing their impact on
the ChE activity or beneficial effects for the treatment of AD. Be-
cause of a lack of AChE inhibitory activity of both representatives,
it was decided not to perform any follow-up studies with this com-
pound group.
2.3.5. Mixed chemical entities
The compounds quinidine and himbacine are the active repre-
sentatives of this group. They differ completely from each other
and from the rest of the compound clusters in terms of their chem-
ical structures. Quinidine possesses a cinchonan scaffold whereas
himbacine represents a decahydronaphthofuranone derivative.
The well-known antiarrhythmic agent quinidine was proven to
be a selective BChE inhibitor with good activity towards the horse
enzyme (7.37 ± 0.03 lM) and even higher potency in inhibiting the
human form, with an IC50 value of 1.23 ± 0.07 lM. The second
compound within this group, himbacine, showed no activity to-
wards BChE in the primary screening (30.1% inhibition at 10 lM)
but was selected as active concerning its AChE inhibitory activity.
Thus, the IC50 value on AChE was determined and found to be
22.7 ± 0.6 lM. Himbacine is known as a potent antagonist of the
M(1) subtype of the muscarinic receptor31 which might be a disad-
vantage in the treatment of Alzheimer’s disease since muscarinic
receptor agonists have shown to cause improvement of cognitive
function and reversal of cognitive deficits.32 This fact together with
the low potency of himbacine against the AChE (lowest among all
the hits) prompted us not to further investigate it on the human
AChE.
2.3.6. Isoquinolines
Palmatine, berberine as well as the benzophenanthridine alka-
loid chelerythrine are clustered together in the isoquinolines group
(Table 2). All three compounds showed good inhibitory activity to-
wards electric eel AChE. Berberine and palmatine displayed a selec-
tive inhibition of the hydrolytic activity of AChE and showed IC50
values of 2.74 ± 0.22 and 4.07 ± 0.09 lM, respectively. Cheleryth-
rine also showed a moderate activity towards AChE
(3.78 ± 0.15 lM). Moreover, this compound further exhibited activ-
ity on horse BChE with an IC50 value of 6.33 ± 0.93 lM. The three
compounds’ activities towards the human enzymes were also eval-
uated. Both berberine and palmatine showed increased activity to-
wards the human AChE, berberine being the most active one
(0.61 ± 0.04 lM). Interestingly, chelerythrine also showed slightly
higher activity towards the human AChE (1.54 ± 0.07 lM, Table 2)
than towards the electric eel AChE (3.78 ± 0.15 lM). A reversed sit-
uation was seen against BChE, as chelerythrine was slightly more
active towards the horse BChE (6.33 ± 0.95 lM) when compared
to the human enzyme (10.34 ± 0.24 lM, Table 2). The only differ-
ence in the chemical structure of palmatine and berberine is the
substitution pattern at the dihydroisoquinoline structure. Accord-
ing to these data, a dioxymethylene substitution is preferred when
compared to vicinal dimethoxy substituents. Moreover, the
A
B
Figure 2. Lineweaver–Burk (left panel) and Dixon (right panel) plots with different substrate concentration [S] in the presence of varying chelerythrine concentrations [I] on
electric eel AChE (A) and human AChE (B).
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increased aromaticity and lipophilicity of chelerythrine due to its
phenanthridine backbone seem to favor the inhibition of both
cholinesterases.
Compared to the compound groups presented earlier,
chelerythrine offers the most attractive compound with good
inhibitory potential of both the AChE and the BChE. Also, from a
medicinal chemistry perspective, the basic scaffold of the isoqui-
noline group could be regarded as a good starting point for chemical
elaborations. Therefore, we selected them, in particular the dual
ChE inhibitor chelerythrine, to proceed with follow-up studies.
2.4. Kinetic mechanism of AChE inhibition
Kinetic studies were performed to determine the inhibition
mechanisms of chelerythrine on the electric eel and the human
AChE. The mechanism of inhibition was graphically determined
by applying the Lineweaver–Burk and Dixon plots. The kinetic
curves revealed that chelerythrine is a mixed inhibitor of electric
eel AChE with a slightly higher competitive behavior
(Kic = 0.48 ± 0.07 lM and Kiuc = 0.92 ± 0.11 lM, Fig. 2A). The same
mechanism of inhibition was found using the human AChE with
Kic = 0.32 ± 0.08 lM and Kiuc = 1.12 ± 0.07 lM (Fig. 2B). Due to the
mixed kinetic mechanism it can be tentatively speculated that
chelerythrine can bind to the PAS.4,33 Hence, we performed
docking studies to elucidate possible interactions between
chelerythrine and the AChE.
2.5. Docking results of chelerythrine on AChE
The crystal structure of 1FSS (from Torpedo californica) was used
as a model receptor for docking chelerythrine, as this structure is
fundamentally similar to the human AChE and it has been exten-
sively used in research. The active site of the AChE consists mainly
of residues TYR70, TRP84, GLY118, GLY119, GLU200, SER201,
ALA226, TRP279, TYR327, PHE330 and HIS440, respectively. Che-
lerythrine covers the active gorge site showing a hydrogen bond
interaction with TYR130 as well as p-stacking interactions with
TYR121 and TYR334 PAS residues (Fig. 3), indicating that this com-
pound can be a very interesting inhibitor with an additional capac-
ity to target the Ab aggregation process. Water molecules are
shown to play an important role in binding of the inhibitors within
the active site of the enzyme. In this case, conserved water
molecules from 1FSS (710, 718, 722, 728) denoted as W1, W2,
W3 andW4 as shown in Figure 3 are found within the catalytic site
and PAS regions, respectively, and may mediate hydrogen bonding
interactions with the active site residues.
2.6. Inhibition of Ab aggregation
In view of earlier results and given the key contribution of amy-
loid b assembly toADpathogenesis,we focused also on the influence
of chelerythrine onamyloidbeta 1–40 (Ab) aggregate formation. The
assay used was based on the typical measurement of the fluores-
cence changes of thioflavin T (ThT). The fact that the in vitro gener-
ationoffluorescent ThT-positiveAb aggregates can take several days
prompted us to apply an acceleratedmethod using 1,1,1,3,3,3-hexa-
fluoro-2-propanol (HFIP) as an aggregation formation enhancer.34
Fluorescence changes of the ThT, typical in the presence of aggre-
gates, were obtained by using a minimal amount of Ab peptide1–40
(0.7 lM) after a relatively short incubation time (45 min) thus
allowingaquick identification of active compoundswithin a reason-
able time frame. Chelerythrine displayed an IC50 value of
4.20 ± 0.43 lM in inhibiting Ab1–40 aggregation. The reference com-
pounds used here were the nordihydroguaiaretic acid, which dis-
played a potency of 18 lM, and the 4-aminophenol, which showed
an inhibition of Ab1–40 assembly of 64% at 250 lM. In comparison,
chelerythrine demonstrated 67% inhibition of Ab1–40 aggregation al-
ready at 10 lM. Moreover, synthetic compounds specifically devel-
oped to inhibit the Ab fibrillogenesis also showed activity in the
micromolar range, like for instance4-hydroxyindolewith an IC50 va-
lue of 85 lM on Ab1–4235 Thus, this suggests that chelerythrine is a
highly active inhibitor of Ab1–40 aggregation.
Berberine and palmatine were also included in these experi-
ments to obtain a better overview of all of the isoquinolines iden-
tified herein. Their potency values were located in the upper
micromolar range (43.84–92.15 lM) (Table 2). These results are
in agreement with recent publications in which the Ab1–42 aggre-
gation inhibitory activities of berberine, benzenediol-hybrid as
well as 9-N-substituted berberine have been reported.33 These
authors have found that berberine causes a 36% aggregation inhibi-
tion at 20 lM. Their most active derivatives, a hydrochinone-ber-
berine hybrid and a 9-N-substituted berberine compound linked
with an ortho methyl phenyl ring, showed 92% and 95% inhibition
at 20 lM, respectively.
2.7. Induction of Ab disaggregation
Having proven the inhibitory properties of these compounds on
preventing the Ab1–40 aggregation, we then evaluated if the iso-
quinolines were able to disaggregate already preformed Ab1–40
aggregates. This assay could be more relevant from a clinical per-
spective. Disaggregation of existing Ab aggregates/fibrils in the
AD brain may be indicated especially at the beginning of the treat-
ment to reduce the neurotoxic effects of Ab aggregates/fibrils and
thus prevent neurodegeneration.
The assay used followed the same general procedure as for
studying the inhibition of Ab1–40 aggregation (ThT assay), but to
obtain aggregates the protein was allowed to assemble 45 min
prior to adding the test compounds. As a positive control for the ef-
fect on Ab1–40 disaggregation, resveratrol was used. In this experi-
mental set-up, a potency of 81.80 ± 3.74 lM was registered for
resveratrol, which is in accordance to previous results showing
that at 10 and 100 lM this compound decreases the ThT fluores-
cence intensity of Ab1–42 fibrils to 71% and 32%, respectively, after
28 h incubation at 37 "C.36 Chelerythrine, once more, showed a
high activity in disaggregating preformed Ab1–40 aggregates with
an IC50 of 13.03 ± 2.89 lM after 45 min incubation. Few
compounds have been found active in Ab disaggregation at low
Figure 3. Chelerythrine within the active site of 1FSS (Torpedo californica AChE).
Water molecules are shown as red spheres.
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micromolar concentrations. The most potent inhibitors so far are
the natural product hyperforin, which reduced Ab1–40 aggregates
to 20% at 100 lM after 4 days incubation, as well as 2,6-diaryl-
1,4-benzoquinone derivatives, which displayed IC50 values on
Ab25–35 between 5 and 14 lM also after 4 days incubation.37,38
We could further show that berberine and palmatine also demon-
strated a remodeling behavior of Ab1–40 aggregates but with lower
activities compared to chelerythrine (IC50 of 105.90 ± 5.90 and
174.3 ± 10.3 lM, respectively).
Nordihydroguaiaretic acid, which inhibits the Ab aggregate for-
mation, does not influence preformed aggregates (Ab1–40)39 and
resveratrol, which is able to dissolve already preformed Ab1–42
aggregates, does not show the ability to inhibit the aggregation
of Ab1–42.36 The already mentioned synthesized 2,5-diaryl and
2,6-diaryl-1,4-benzoquinones displayed a bivalent behavior on
Ab25–35 aggregation37 but have not been proven to act as cholines-
terase inhibitors. In the case of chelerythrine, we describe for the
first time, to the best of our knowledge, a dual cholinesterase
inhibitor acting on AChE and BChE, with additional ability not only
to inhibit the Ab1–40 aggregation but also to disaggregate pre-
formed Ab1–40 aggregates.
2.8. Inhibition of AChE-induced Ab fibril formation by
chelerythrine
In contrast to the accelerated method using HFIP as aggregation
enhancer, the experimental procedure that uses AChE as promoter
of fibril formation resembles better the processes taking place in
the AD brain. Inestrosa et al. demonstrated in vitro that recombi-
nant human AChE directly enhances the aggregation of Ab1–40 pep-
tide into fibrils, forming a stable AChE-Ab complex.2 The fact that
AChE inhibitors are already clinically used to restore the choliner-
gic balance and that AChE seems to be strongly involved in the Ab
fibril formation process stresses the importance of identifying
compounds that can potentially target the pro-aggregating effect
of AChE as well as its hydrolase activity. However, the role of BChE
in AD should not be neglected. It is known that BChE is able to
compensate for the lower activity of AChE detected at the later
stages of the AD pathogenesis40 giving good grounds for using
compounds which act as dual inhibitors to efficiently slow down
the hydrolysis of acetylcholine.
The identification of chelerythrine as mixed inhibitor as well as
the results of the docking study, (indicating that this compound
likely interacts with PAS), increased the likelihood that the com-
pound may also inhibit AChE-induced Ab aggregation. Indeed, as
seen in Table 3, chelerythrine inhibited AChE-induced Ab aggrega-
tion at 5, 10 and 100 lMwith 48.5%, 65.0% and 88.4%. No inhibition
was detected at a concentration of 1 lM. Propidium iodide was
included as a positive control in our experiments at the concentra-
tions 10 and 100 lM, which caused an inhibition of AChE-induced
Ab fibril formation of 33.9% and 93.1%, respectively. These values
are comparable to those found in the literature. An inhibition of
82% at 100 lM of propidium iodide has been reported on
Ab1–40.41 Propidium iodide is a non-competitive AChE inhibitor
(IC50 value of 32.2 ± 2.2 lM on the human AChE) and it has been
found to bind to the PAS region of the enzyme.2,4 Compounds de-
scribed in the literature are regarded as good inhibitors of AChE-
induced Ab fibril formation if they exhibit biological activity in
the range of 82–98% at 100 lM.42 Compared to these data,
chelerythrine can also be classified as a potent inhibitor of AChE-
induced Ab1–40 aggregation. Accordingly, the biological character-
istics of chelerythrine described herein make this compound a
promising lead for the development of potent AD-modifying drugs.
3. Conclusion
Because of the fact that AD is a complex multifactorial disorder,
the use of compounds able to modify several targets simulta-
neously is considered to be a successful strategy in the treatment
of this disease. Based on the screening of a natural product library
towards AChE and BChE inhibition we clustered the identified hits
according to structural similarities into six different compound
classes. Starting from this classification we investigated the com-
pounds in-depth and selected the isoquinolines as the most prom-
ising group, especially the compound chelerythrine.
The three members of the isoquinoline group (berberine, palm-
atine and chelerythrine) showed selective activity towards the
butyrylcholinesterase (berberine and palmatine) and activity to-
wards both the acetyl- and butyrylcholinesterase (chelerythrine)
as well as ability to prevent the aggregation of Ab peptide into
fibrils and to disaggregate preformed Ab aggregates, the latter
being very interesting as a more relevant property applicable to
the clinical context. The most promising molecule was identified
as chelerythrine due to its better potencies and effects on both
AChE and BChE. Moreover, this compound also showed inhibition
of AChE-induced Ab fibril formation. For the first time, we describe
a compound able to inhibit AChE and BChE, having the potency to
impede self- as well as AChE-induced aggregation and possessing
the capacity to disaggregate preformed Ab aggregates. Recently,
Niu et al. tested chelerythrine on primary peritoneal macrophages
and they detected no cytotoxic activity of the compound.43 In vivo
treatment of SQ-20B-bearing mice (head and neck cancer) led to
tumor growth delay with only minimal toxicity resulting from
the treatment with chelerythrine.44 Thus, it seems to be a well-tol-
erated compound. In addition, as mentioned earlier, the benzophe-
nanthridine backbone of the chelerythrine opens routes for
medicinal chemists. This scaffold provides a certain number of
positions that can be chemically modified in a fast way (e.g., meth-
oxy groups, aromatic rings, positively charged nitrogen) which is a
desirable requirement to undertake future lead optimization
endeavors. Altogether, these features make chelerythrine an excel-
lent starting point in the search for more effective strategies target-
ing cholinergic restoration and Ab fibril formation.
4. Experimental
4.1. Compound library and screening
The commercially available Enzo# Screen-Well# Natural Prod-
uct Library (Enzo Life Sciences Inc., USA) consisting of 502 natural
and naturally derived compounds (common names given in the
Supplementary Table S1) was prepared in DMSO at a concentration
of 2 mg/ml and maintained at !70 "C. Prior to usage, compounds
were thawed at +37 "C in a water bath, following the manufac-
turer’s recommendations. In order to facilitate the screening pro-
cess, the natural product library was transferred to 96-well
microplates using Biomek 3000 liquid handling workstation
(Beckman Coulter, USA). In this step, the compounds were diluted
Table 3
Inhibition of AChE-induced Ab1–40 fibrillogenesis by chelerythrine and the control
compound propidium iodide at different concentrations
Compound Concentration
(lM)
Inhibition of AChE-induced Ab
fibrillogenesis (%) ± SD
Chelerythrine 1 0.8 ± 0.1
5 48.5 ± 3.7
10 65.0 ± 0.3
100 88.4 ± 1.0
Propidium
iodide
10 33.9 ± 4.4
100 93.1 ± 2.2
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in Tris–HCl 50 mM pH 8 (the reaction buffer) to concentrations
ranging from 1.624 to 0.117 mM. These plates were kept at +4 "C
for not longer than one week, before starting the screening runs.
4.2. Exploration of the chemical space of the library
To study the chemical space occupied by the natural product li-
brary the Principal Component Analysis (PCA)-based chemical
space navigation tool ChemGPS-NP was used.17 The analysis is
based on 2D descriptors (total of 35) describing physical-chemical
properties of the compounds and calculated from SMILES (ob-
tained by the web-based programs ChemSpider or Molinspiration
Chemoinformatics v2009.01). Differences in stereochemistry were
ignored as only 2D descriptors were taken into consideration. Salts,
hydration information as well as counter-ions were excluded from
the SMILES annotation. For analysis of the chemical space, the first
four dimensions (PC1-PC4) were plotted using the software Gra-
pher 2.1 (MacOS X, US).
4.3. Assays for measuring AChE and BChE activity
The kinetic assay used to screen for inhibition of the hydrolase
activity of AChE as well as BChE is based on the Ellman’s reaction14
and was carried out as described by Karlsson et al.18 The substrate
concentration in both cholinesterases assay was 1.5 mM. The final
concentration of the test compounds in the 96-well microplate was
between 2.35 and 32.65 lM (average concentration: 17.50 lM) in
Tris–HCl 50 mM pH 8. As control samples, 10 lM physostigmine
dissolved in methanol (reference inhibitor) or DMSO:buffer Tris–
HCl 50 mM pH 8 (solvent control) were included. The starting step
of the enzymatic reaction was the addition of 0.224 U/ml AChE (EC
3.1.1.7, from Electric eel, Sigma–Aldrich, USA) or 0.198 U/ml hu-
man AChE (EC 3.1.1.7, from human erythrocytes, dissolved in
0.02 M HEPES pH 8 containing 0.1% Triton X-100, Sunnylab#, UK)
in Tris–HCl 50 mM pH 8 containing 0.1% BSA. For testing against
BChE, 0.350 U/ml BChE (EC 3.1.1.8, from horse serum, Sigma–Al-
drich, USA) or 0.192 U/ml recombinant human BChE (EC 3.1.1.8,
expressed in transgenic goat, Sigma–Aldrich, USA) in Tris–HCl
50 mM pH 8 containing 0.1% BSA were added. Spontaneous and
enzymatic hydrolysis were measured before and after enzyme
addition, respectively, three times during 10 min at k = 412 nm
using a Varioskan Flash multimode plate reader (Thermo Fisher
Scientific, Finland).
4.4. Potency determination and kinetic analysis
According to the results obtained by the first screening, suitable
concentration steps were selected for the active compounds to
determine potency (IC50) values. All compounds regarded as selec-
tive were tested against their preferential target (AChE or BChE)
and unselective inhibitors were further investigated on both en-
zymes. In each case, potencies were calculated with at least nine
different concentrations, tested in four replicates in two indepen-
dent experiments. Kinetic experiments were carried out in accor-
dance to the previously described AChE/BChE assay (Section 4.3).
Chelerythrine was tested at different concentrations (0.5–2.5 lM
against AChE and 0.5–1.5 lM against human AChE) with substrate
(ATCI) concentration ranging from 0.2 to 2.0 mM. Conventional
Lineweaver–Burk double-reciprocal (1/V vs 1/[S]) and Dixon (1/V
vs [I]) kinetic plots were used to identify the inhibition type and
to calculate the Ki value as in Karlsson et al.18
4.5. Docking studies
Molecular docking of the compound was done using Glide mod-
ule in Schrödinger package using Torpedo californica AChE (AChE)
crystal structure 1FSS (resolution 3 Å).45 The protein was prepared
using the Protein Preparation Wizard in Schrödinger (Schrödinger
Suite 2011 Protein Preparation Wizard; Epik version 2.2, Ligprep
2.5, Glide 5.7, New York). In this wizard the bond orders are as-
signed, hydrogen atoms are added and atom types are defined,
and the charge and protonation states are also corrected. The ter-
mini were subjected to capping and the protein was energy mini-
mized up to 0.3 ÅA
0
RMSD. All the important and conserved
crystallographic water molecules were retained. The ligand struc-
ture was drawn in Maestro. The molecule was prepared using Lig-
prep module with MMFF force field and the grid was defined using
the centroid of the active site residues. The option to dock flexibly
with standard precision was selected.
4.6. Assay for measuring inhibition of Ab1–40 aggregation using
HFIP
Aggregates formation was measured by the thioflavin T (ThT)
assay46 using the Ab1–40 peptide, which is based on the fact that
in presence of Ab1–40 aggregates, a shift in the emission and excita-
tion spectra of ThT occurs (kexcitation = 385 nm and kemission
= 445 nm to kexcitation = 450 nm and kemission = 482 nm).46 The com-
pounds were assayed using the Ab1–40 peptide according to the
protocol described by Liu et al.47 with several modifications as
indicated in Karlsson et al.18 Compounds were tested in concentra-
tions between 1 and 250 lM in three replicates. Immediately after
adding the protein as well as after 45 min incubation at 37 "C and
vigorous shaking (1000 rpm) the fluorescence was measured. As a
reference compound, nordihydroguaiaretic acid,48 dissolved in
DMSO and diluted in methanol/buffer 2:1 to obtain a final
concentration of 20 lM, was used. In case of berberine, pal-
matine and chelerythrine the same experiments were performed
without protein and the resulted values were subtracted from
the data obtained with protein.
4.7. Assay for measuring disaggregation of preformed Ab1–40
aggregates
The compounds’ disaggregation behavior of preformed aggre-
gates was measured by the ThT assay using the Ab1–40. The same
peptide, buffers as well as procedure were used as in Section 4.6
with the following changes. First, peptide and ThT were incubated
at 37 "C and vigorous shaking (1000 rpm). After 45 min the fluores-
cence was measured. The test compounds were added immedi-
ately in concentrations between 0.5 and 250 lM and incubated
at the same conditions for another 45 min. The reference com-
pound, resveratrol,36 was dissolved in DMSO and diluted in meth-
anol/buffer 2:1 to obtain a final concentration of 100 lM. The same
experiments were performed without peptide and the resulted val-
ues were subtracted from the data obtained with Ab.
4.8. Assay for measuring inhibition of Ab1–40 fibril formation
induced by AChE
Experiments were carried out in analogy to the procedure de-
scribed by Inestrosa et al.2 Immediately prior to use, an Ab1–40 ali-
quot was dissolved in 25 ll 0.1 M Tris–HCl, pH 7.4, to obtain a final
concentration of 230 lM. Stock solutions of the test compound
were prepared in 0.1 M Tris–HCl, pH 7.4, and aliquotes of AChE
(electric eel) were prepared in 0.1 M sodium phosphate buffer,
pH 8, to achieve a final concentration of 2.3 lM (final molar ratio
protein–enzyme 100:1). The test compound was added to reach a
final concentration of 1, 5, 10 and 100 lM. Incubations were per-
formed on a 96-well microtiter plate. To quantitate amyloid beta
fibril formation, 1.5 lM final ThT concentration in 50 mM glycine
buffer pH 9.0 was added and the fluorescence was immediately
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measured (excitation wavelength 440 nm, emission wavelength
485 nm) on a Thermo Scientific Varioskan Flash spectral scanning
multimode reader after incubation for 24 h at 25 "C. Background
fluorescence of 1.5 lM ThT was subtracted.
4.9. Statistical analysis and data processing
In the first primary screening against both targets (AChE and
BChE), each compound was tested in a single well. During the fol-
low-up studies at least 2 replicates were used and potency deter-
mination experiments were repeated at least twice. IC50 values
were calculated via non-linear regression analysis (sigmoidal fit-
ting with variable slope) using GraphPad Prism v. 4.0 (GraphPad
software Inc., US). Typical statistical parameters (S/N ratio, S/B ra-
tio, Z0 factor and CVA) to characterize the quality of screening as-
says were calculated for each as indicated by Karlsson et al.18
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